FDA delivers warning to Chinese company after no response to Form 483

By Ben Hargreaves

- Last updated on GMT

(Image: Getty/Seb_Ra)
(Image: Getty/Seb_Ra)

Related tags Fda China Warning letter Yino

US FDA sends a warning letter to Yino, after the company failed to provide a response to issues raised in a Form 483 regarding relabeling of API.

In the warning letter​, the US Food and Drug Administration (FDA) highlighted that inspections revealed issues, which had previously led to the issuance of Form 483, regarding relabeling active pharmaceutical ingredient (API) without noting the original manufacturer and failure in quality control.

The FDA stated that it had not received a response regarding corrective action taken to the two observations noted and had placed Yino Inc. on Import Alert 66-40 on August 1, 2019.

Yino is a Chinese company located in Chongqing and supplies asparaginase to the US market, a spokesperson for the company told us.

The warning letter notes, “[The company] re-labels API manufactured by other manufacturers and distribute the API to other facilities.”

The FDA identified that the relabeled API did not feature the name or address of the original manufacturer on certificates of analysis (COA). The agency highlighted that regulators and customers rely on COA for accurate information about the quality and source of drugs.

In addition, the agency observed that the COA of several lots of the company’s API did not feature a signature or date from an authorized person in the quality unit.

On these lots, the FDA found “a test parameter and result that was not performed by the original API manufacturer, nor could [the company] provide evidence that [it] had performed the test.”

The spokesperson told us, "Response to Form 483 was sent to and confirmed by the FDA's Office for Pharmaceutical Quality Operations. However, it appears the Center for Drug Evaluation and Research Office of Manufacturing Quality did not receive the response and issued the warning letter."

The company has since submitted a response to the waning letter and "expects that the warning letter will be withdrawn soon,"​ the spokesperson confirmed.

Update: The article has been updated to correct the named company to Yino Inc., and quotes have been added by the company involved.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us


View more